Torcetrapib/atorvastatin

Drug Profile

Torcetrapib/atorvastatin

Alternative Names: Atorvastatin/torcetrapib

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics; Fatty acids; Heptanoic acids; Pyrroles; Quinolines
  • Mechanism of Action Cholesterol ester transfer protein inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Coronary disorders; Hyperlipidaemia; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol

Most Recent Events

  • 02 Dec 2006 Discontinued - Phase-III for Coronary disorders in Australia (PO)
  • 02 Dec 2006 Discontinued - Phase-III for Coronary disorders in Canada (PO)
  • 02 Dec 2006 Discontinued - Phase-III for Coronary disorders in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top